A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma-Reference-Cited by-同舟云学术

A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma

Published:2020-01-27 Issue:5 Volume:38 Page:1421-1429
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Smith David C.,Kroiss Matthias,Kebebew Electron,Habra Mouhammed Amir,Chugh Rashmi,Schneider Bryan J.,Fassnacht Martin,Jafarinasabian Pegah,Ijzerman M. Marian,Lin Vivian H.,Mohideen Pharis,Naing Aung

Funder

Millendo Therapeutics, Inc.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-020-00899-1.pdf

Reference19 articles.

1. Fassnacht M, Libé R, Kroiss M, Allolio B (2011) Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 7(6):323–335. https://doi.org/10.1038/nrendo.2010.235 Epub 2011 Mar 8

2. Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM et al (2014) Adrenocortical carcinoma. Endocr Rev 35(2):282–326 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24423978

3. Kebebew E, Reiff E, Duh Q-Y, Clark OH, McMillan A (2006) Extent of Disease at Presentation and Outcome for Adrenocortical Carcinoma: Have We Made Progress? World J Surg 30(5):872–878 Available from: http://www.ncbi.nlm.nih.gov/pubmed/16680602

4. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, Van de Poll-Franse LV, Haak HR (2013) Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer 49(11):2579–2586

5. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F et al (2009) Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 115(2):243–250. https://doi.org/10.1002/cncr.24030

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of Stealth Liposome-Based Nanoparticles Encapsulating the ACAT1/SOAT1 Inhibitor F26: Efficacy and Toxicity Studies In Vitro and in Wild-Type Mice;International Journal of Molecular Sciences;2024-08-23

2. Systemic Management of Advanced Adrenocortical Carcinoma;Current Treatment Options in Oncology;2024-07-27

3. Current and Emerging Pharmacological Therapies for Cushing's Disease;Current Pharmaceutical Design;2024-03

4. Current Status and Future Direction in the Treatment of Advanced Adrenocortical Carcinoma;Current Oncology Reports;2024-02-21

5. Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches;The Oncologist;2024-02-21